Trial sponsors
848 lead sponsors across 2,348 registered phase 2 and 3 studies and 136 curated trials: 177 companies, 49 cooperative groups and 342 institutions, plus names not yet mapped. Filter by cancer to see who runs the most trials in it.
848 sponsors
| # | Top indications | |||||||
|---|---|---|---|---|---|---|---|---|
| 1 | National Cancer Institute (NIH) Government or charity | 126 | 124 | 13 | 116 | 18 | ||
| 2 | Novartis Company | 83 | 21 A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMAA Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC+18 | 62 | 37 | 35 | 6 | |
| 3 | MD Anderson Cancer Center Institution | 61 | 0 | 61 | 2 | 59 | 5 | |
| 4 | AstraZeneca Company | 40 | 33 | 16 | 19 | 3 | ||
| 5 | Mayo Clinic Institution | 34 | 0 | 34 | 4 | 31 | 8 | |
| 6 | Memorial Sloan Kettering Cancer Center Institution | 30 | 0 | 30 | 1 | 29 | 6 | |
| 7 | Bayer Company | 30 | 28 | 11 | 20 | 0 | ||
| 8 | Alliance for Clinical Trials in Oncology Cooperative group | 25 | 24 | 11 | 15 | 3 | ||
| 9 | 24 | 0 | 24 | 1 | 24 | 5 | ||
| 10 | Fred Hutch / University of Washington Institution | 23 | 0 | 23 | 0 | 23 | 7 | |
| 11 | Avid Radiopharmaceuticals Company | 22 | 0 | 22 | 9 | 15 | 0 | |
| 12 | Dana-Farber Brigham Cancer Center Institution | 22 | 0 | 22 | 5 | 17 | 0 | |
| 13 | Merck & Co. (MSD) Company | 22 | 0 | 22 | 15 | 7 | 6 | |
| 14 | Sanofi Company | 22 | 21 | 6 | 15 | 0 | ||
| 15 | GSK Company | 21 | 20 | 4 | 17 | 2 | ||
| 16 | Roche / Genentech Company | 21 | 20 | 7 | 13 | 0 | ||
| 17 | Pfizer (incl. Seagen) Company | 20 | 18 | 10 | 10 | 1 | ||
| 18 | Sun Yat-sen University Cancer Center Institution | 19 | 0 | 19 | 3 | 16 | 6 | |
| 19 | Bristol Myers Squibb Company | 19 | 16 | 7 | 10 | 2 | ||
| 20 | Fudan University Shanghai Cancer Center Institution | 18 | 0 | 18 | 4 | 14 | 4 | |
| 21 | UCLA Jonsson Comprehensive Cancer Center Institution | 18 | 0 | 18 | 3 | 15 | 7 | |
| 22 | Winship Cancer Institute (Emory) Institution | 18 | 0 | 18 | 1 | 18 | 2 | |
| 23 | Children's Oncology Group Cooperative group | 18 | 16 | 15 | 5 | 4 | ||
| 24 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd Company | 16 | 0 | 16 | 5 | 12 | 0 | |
| 25 | Johnson & Johnson Company | 16 | 14 | 8 | 8 | 2 | ||
| 26 | EORTC Cooperative group | 14 | 0 | 14 | 5 | 9 | 2 | |
| 27 | Tianjin Medical University Cancer Institute and Hospital Institution | 14 | 0 | 14 | 1 | 13 | 2 | |
| 28 | Gustave Roussy Institution | 14 | 13 | 6 | 8 | 1 | ||
| 29 | Massachusetts General Hospital Institution | 13 | 0 | 13 | 0 | 13 | 2 | |
| 30 | Astellas Company | 13 | 12 | 3 | 10 | 1 | ||
| 31 | Asan Medical Center Institution | 12 | 0 | 12 | 2 | 10 | 1 | |
| 32 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Cooperative group | 12 | 0 | 12 | 4 | 8 | 1 | |
| 33 | Peking Union Medical College Hospital Institution | 12 | 0 | 12 | 3 | 11 | 0 | |
| 34 | SWOG Cooperative group | 12 | 0 | 12 | 3 | 9 | 2 | |
| 35 | ECOG-ACRIN Cooperative group | 12 | 11 | 5 | 8 | 3 | ||
| 36 | GE HealthCare Company | 12 | 10 | 8 | 3 | 0 | ||
| 37 | Jiangsu Hengrui Company | 12 | 4 A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate CancerA Trial of HRS-6213 in Healthy Subjects and Patients With Solid TumorsA Trial of HRS-6768 in Patients With Advanced Solid Tumors+1 | 8 | 7 | 3 | 2 | |
| 38 | Chang Gung Memorial Hospital Institution | 11 | 0 | 11 | 1 | 11 | 1 | |
| 39 | Northwestern (Lurie) Institution | 11 | 0 | 11 | 0 | 11 | 1 | |
| 40 | Princess Margaret Cancer Centre Institution | 11 | 0 | 11 | 1 | 11 | 2 | |
| 41 | AHS Cancer Control Alberta Unmapped | 10 | 0 | 10 | 2 | 9 | 0 | |
| 42 | City of Hope Institution | 10 | 0 | 10 | 1 | 9 | 4 | |
| 43 | Moffitt Cancer Center Institution | 10 | 0 | 10 | 0 | 10 | 0 | |
| 44 | Navidea Biopharmaceuticals Company | 10 | 0 | 10 | 5 | 5 | 0 | |
| 45 | NRG Oncology (RTOG, GOG, NSABP) Cooperative group | 10 | 0 | 10 | 3 | 7 | 2 | |
| 46 | O'Neal Cancer Center at UAB Institution | 10 | 0 | 10 | 0 | 10 | 2 | |
| 47 | Peking University Cancer Hospital Institution | 10 | 0 | 10 | 4 | 7 | 2 | |
| 48 | UNICANCER Cooperative group | 10 | 0 | 10 | 3 | 8 | 1 | |
| 49 | UW Carbone Cancer Center Institution | 10 | 0 | 10 | 1 | 9 | 2 | |
| 50 | Weill Medical College of Cornell University Institution | 10 | 0 | 10 | 0 | 10 | 3 | |
| 51 | Lantheus Company | 10 | 7 | 6 | 3 | 0 | ||
| 52 | Blue Earth Diagnostics Company | 10 | 5 | 7 | 1 | 0 | ||
| 53 | Peter MacCallum Cancer Centre Institution | 10 | 5 | 1 | 5 | 1 | ||
| 54 | Telix Pharmaceuticals Company | 10 | 5 | 10 | 0 | 3 | ||
| 55 | Columbia (Herbert Irving) Institution | 9 | 0 | 9 | 1 | 9 | 1 | |
| 56 | Duke Cancer Institute Institution | 9 | 0 | 9 | 0 | 9 | 1 | |
| 57 | University of Michigan Rogel Institution | 9 | 0 | 9 | 0 | 9 | 1 | |
| 58 | Molecular Partners Company | 9 | 8 | 1 | 7 | 0 | ||
| 59 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS Unmapped | 8 | 0 | 8 | 0 | 8 | 2 | |
| 60 | Radboud University Medical Center Institution | 8 | 0 | 8 | 4 | 5 | 0 | |
| 61 | Seoul National University Hospital Institution | 8 | 0 | 8 | 1 | 7 | 4 | |
| 62 | University of California, San Francisco Institution | 8 | 0 | 8 | 0 | 8 | 1 | |
| 63 | University of Southern California Institution | 8 | 0 | 8 | 0 | 8 | 0 | |
| 64 | University of Texas Southwestern Medical Center Institution | 8 | 0 | 8 | 0 | 8 | 2 | |
| 65 | University of Utah Institution | 8 | 0 | 8 | 0 | 8 | 0 | |
| 66 | Boston Scientific Corporation Unmapped | 8 | 7 | 5 | 2 | 0 | ||
| 67 | UCL / UCLH Institution | 8 | 1 | 7 | 4 | 4 | 2 | |
| 68 | Assistance Publique - Hôpitaux de Paris Unmapped | 7 | 0 | 7 | 2 | 5 | 2 | |
| 69 | Eli Lilly (incl. Loxo) Company | 7 | 0 | 7 | 3 | 5 | 0 | |
| 70 | Istituto Nazionale dei Tumori Institution | 7 | 0 | 7 | 0 | 7 | 0 | |
| 71 | SCRI Development Innovations, LLC Unmapped | 7 | 0 | 7 | 0 | 7 | 0 | |
| 72 | St. Jude Children's Research Hospital Institution | 7 | 0 | 7 | 0 | 7 | 2 | |
| 73 | Vanderbilt-Ingram Institution | 7 | 0 | 7 | 1 | 6 | 2 | |
| 74 | 6 | 0 | 6 | 1 | 6 | 0 | ||
| 75 | Amgen Company | 6 | 0 | 6 | 2 | 4 | 1 | |
| 76 | Barbara Ann Karmanos Cancer Institute Institution | 6 | 0 | 6 | 0 | 6 | 0 | |
| 77 | CAMS Cancer Hospital Institution | 6 | 0 | 6 | 2 | 4 | 1 | |
| 78 | Case Comprehensive Cancer Center Institution | 6 | 0 | 6 | 0 | 6 | 1 | |
| 79 | Cedars-Sinai Medical Center Institution | 6 | 0 | 6 | 1 | 5 | 0 | |
| 80 | Georgetown University Institution | 6 | 0 | 6 | 0 | 6 | 0 | |
| 81 | Merck KGaA (EMD Serono) Company | 6 | 0 | 6 | 4 | 2 | 0 | |
| 82 | Netherlands Cancer Institute Institution | 6 | 0 | 6 | 1 | 5 | 2 | |
| 83 | OHSU Knight Cancer Institute Institution | 6 | 0 | 6 | 0 | 6 | 1 | |
| 84 | Siteman Cancer Center (WashU) Institution | 6 | 0 | 6 | 0 | 6 | 2 | |
| 85 | Spanish Oncology Genito-Urinary Group Cooperative group | 6 | 0 | 6 | 0 | 6 | 0 | |
| 86 | Spectrum Pharmaceuticals, Inc Company | 6 | 0 | 6 | 4 | 2 | 0 | |
| 87 | Stanford Institution | 6 | 0 | 6 | 0 | 6 | 0 | |
| 88 | UPMC Hillman Cancer Center Institution | 6 | 0 | 6 | 1 | 5 | 0 | |
| 89 | Exelixis Company | 6 | 4 | 5 | 1 | 0 | ||
| 90 | Cancer Research UK Government or charity | 6 | 2 | 2 | 2 | 0 | ||
| 91 | British Columbia Cancer Agency Government or charity | 5 | 0 | 5 | 2 | 3 | 0 | |
| 92 | Chinese University of Hong Kong Institution | 5 | 0 | 5 | 1 | 4 | 1 | |
| 93 | CHU de Quebec-Universite Laval Institution | 5 | 0 | 5 | 0 | 5 | 0 | |
| 94 | Copenhagen University Hospital, Rigshospitalet Institution | 5 | 0 | 5 | 0 | 5 | 0 | |
| 95 | Fondazione Italiana Linfomi - ETS Unmapped | 5 | 0 | 5 | 2 | 3 | 0 | |
| 96 | Grupo Espanol de Tumores Neuroendocrinos Unmapped | 5 | 0 | 5 | 3 | 2 | 2 | |
| 97 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Institution | 5 | 0 | 5 | 0 | 5 | 0 | |
| 98 | Institute of Cancer Research Institution | 5 | 0 | 5 | 2 | 3 | 1 | |
| 99 | Nanfang Hospital, Southern Medical University Institution | 5 | 0 | 5 | 2 | 5 | 0 | |
| 100 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Institution | 5 | 0 | 5 | 0 | 5 | 3 |
(showing the first 100)
Sources
Registry studies are the phase 2 and 3 studies ClinicalTrials.gov returns for each product in the corpus (public/trials/*.json, fetched 2026-10-19), de-duplicated by NCT id and credited to the lead sponsor. Because they are found through products, sponsors of trials that name no corpus product are under-counted, and academic sponsors of investigator-initiated studies appear alongside the companies whose drugs they test.
Landmark trials are the curated trials in the corpus, credited to each party in the sponsor field (“AstraZeneca / Daiichi Sankyo” counts for both).
Names and indications
Sponsor strings are normalised to company, institution and cooperative-group ids in src/data/sponsor-aliases.ts; acquired companies roll up to the acquirer. About 47% of study credits belong to names with no mapping yet and appear under the name as written. Cancers are matched from the registered condition text to corpus indications by name and alias; a study counts under a cancer only when the text names it.
Compare with trial leadership, which ranks institutions by their presence in the landmark trials, and the company records.